# The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

> **NCT00002347** · PHASE2 · COMPLETED · sponsor: **Parexel** · enrollment: 225 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Saquinavir
- **DRUG:** Nevirapine
- **DRUG:** Zidovudine
- **DRUG:** Zalcitabine

## Key facts

- **NCT ID:** NCT00002347
- **Lead sponsor:** Parexel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 225 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002347, "The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*